Five Promising Drugs Heading to FDA Decision in January 2026—Here's What Could Change Treatment

Five medications are awaiting FDA approval decisions in January 2026, with several poised to become the first treatments of their kind for serious conditions. These drugs represent years of clinical research and could significantly expand treatment options for patients with rare cancers, kidney disease, allergies, and vision problems. The approvals could reshape how doctors manage everything from life-threatening allergic reactions to post-transplant complications.

What Is the FDA Review Timeline and Why Does It Matter?

The FDA sets review deadlines called Prescription Drug User Fee Act (PDUFA) dates for new drug applications. Most medications receive a standard 10-month review period after the FDA accepts the application. However, drugs addressing serious unmet medical needs can qualify for Priority Review, which cuts the timeline to just 6 months. This faster track means patients with life-threatening conditions may gain access to new treatments more quickly.

Which Five Medications Are Under Review?

The January 2026 FDA decisions will focus on treatments spanning multiple medical specialties. Each addresses a different patient population, from children recovering after organ transplants to adults struggling with presbyopia, a common age-related vision problem.

• Tabelecleucel for Post-Transplant Lymphoproliferative Disease: This allogeneic T-cell immunotherapy targets EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD), a rare and potentially deadly blood cancer that can develop after solid organ or stem cell transplantation. The drug received Priority Review based on phase 3 ALLELE study data showing an objective response rate of 48.8% in patients who had failed prior therapies. If approved, it would be the first allogeneic T-cell therapy available in the United States for this indication.
• Sparsentan for Focal Segmental Glomerulosclerosis: This oral medication combines an endothelin and angiotensin II receptor antagonist to treat focal segmental glomerulosclerosis (FSGS), a rare kidney disease and leading cause of end-stage renal disease. Phase 3 DUPLEX study findings showed sparsentan significantly reduced proteinuria (excess protein in urine) compared with irbesartan in children and adults with FSGS. Approval would make it the first treatment specifically designed for this condition.
• Trastuzumab Deruxtecan Plus Pertuzumab for Breast Cancer: This combination therapy targets HER2-positive metastatic breast cancer in the first-line setting. The phase 3 DESTINY-Breast09 trial demonstrated that the combination achieved a median progression-free survival of 40.7 months compared with 26.9 months for standard chemotherapy plus trastuzumab and pertuzumab. The confirmed objective response rate was 85.1% versus 78.6%, respectively.
• Brimochol PF for Presbyopia: This preservative-free combination of carbachol and brimonidine tartrate addresses presbyopia, the age-related difficulty focusing on near objects that affects millions of adults over 45. Phase 3 BRIO-I and BRIO-II trials showed the combination significantly improved near and distance binocular visual acuity compared with either drug alone, with pupil size reductions lasting up to 10 hours.
• Anaphylm (Sublingual Epinephrine Film) for Severe Allergic Reactions: This needle-free, orally delivered epinephrine product represents a breakthrough for anaphylaxis treatment. The sublingual film dissolves rapidly and delivers epinephrine systemically without injection. In an Oral Allergy Syndrome challenge study, Anaphylm resulted in rapid symptom resolution beginning just 2 minutes after administration. If approved, it would be the first and only orally delivered epinephrine product for severe allergic reactions.

How Do These Clinical Trials Support FDA Approval?

Each medication underwent rigorous randomized controlled trials to demonstrate safety and effectiveness. The tabelecleucel application drew support from the ALLELE study, which enrolled patients with EBV+ PTLD who had already failed at least one prior therapy, making the 48.8% response rate particularly meaningful for this treatment-resistant population. Similarly, the sparsentan trials included both children and adults, ensuring the drug's safety profile spans age groups likely to benefit from treatment.

The breast cancer combination therapy showed clinically meaningful improvements in survival metrics. The 13.8-month difference in median progression-free survival between the new combination and standard care represents a substantial benefit for patients with metastatic disease. The 85.1% objective response rate means the majority of patients experienced tumor shrinkage or disappearance.

For the presbyopia treatment, the trials specifically measured real-world outcomes like reading speed and quality of life, not just visual acuity numbers. This approach reflects how patients actually experience the medication's benefits in daily activities.

Why Should Patients Care About These Approvals?

These medications address significant gaps in current treatment options. EBV+ PTLD patients currently have limited choices after rituximab failure, making tabelecleucel a potentially life-saving option. Patients with focal segmental glomerulosclerosis have faced a disease with no specific treatment, only symptom management and eventual kidney transplantation. The new breast cancer combination could extend survival for thousands of women annually. And for the estimated 128 million Americans with presbyopia, Brimochol PF offers a pharmaceutical alternative to reading glasses or surgery.

The epinephrine film addresses a critical safety gap. Current epinephrine auto-injectors require intramuscular injection, which can be difficult for patients with mobility issues, anxiety about needles, or difficulty accessing their thigh in emergency situations. A sublingual film eliminates these barriers while maintaining rapid drug delivery.

Steps to Stay Informed About FDA Drug Approvals

• Check the FDA Website: Visit FDA.gov and search the drug approval calendar to track PDUFA dates for medications relevant to your health conditions or those affecting family members.
• Review Clinical Trial Data: Search ClinicalTrials.gov using the study identifiers mentioned in FDA applications to read detailed results from phase 3 trials before drugs reach the market.
• Consult Your Healthcare Provider: Discuss newly approved medications with your doctor to understand whether they might be appropriate for your specific diagnosis, medical history, and current treatment plan.
• Follow Medical News Sources: Subscribe to specialty medical publications covering your condition to receive updates when FDA decisions are announced and new treatments become available.

The January 2026 FDA decisions represent the culmination of years of research and clinical testing. Whether these medications ultimately receive approval, they demonstrate how the drug development pipeline continues advancing treatment options for conditions that previously had few or no effective therapies. Patients and healthcare providers should monitor these decisions closely, as approval could meaningfully change how doctors manage rare cancers, kidney disease, metastatic breast cancer, presbyopia, and life-threatening allergic reactions.